Targeting the trypanosome kinetochore with CLK1 protein kinase inhibitors
نویسندگان
چکیده
منابع مشابه
Targeting cancer with kinase inhibitors.
Kinase inhibitors have played an increasingly prominent role in the treatment of cancer and other diseases. Currently, more than 25 oncology drugs that target kinases have been approved, and numerous additional therapeutics are in various stages of clinical evaluation. In this Review, we provide an in-depth analysis of activation mechanisms for kinases in cancer, highlight recent successes in d...
متن کاملTargeting the RAS pathway by mitogen-activated protein kinase inhibitors.
Targeting of oncogenic driver mutations with small-molecule inhibitors resulted in powerful treatment options for cancer patients in recent years. The RAS (rat sarcoma) pathway is among the most frequently mutated pathways in human cancer. Whereas targeting mutant Kirsten RAS (KRAS) remains difficult, mutant B rapidly accelerated fibrosarcoma (BRAF) kinase is an established drug target in cance...
متن کاملRegulated targeting of protein phosphatase 1 to the outer kinetochore by KNL1 opposes Aurora B kinase
Regulated interactions between kinetochores and spindle microtubules are essential to maintain genomic stability during chromosome segregation. The Aurora B kinase phosphorylates kinetochore substrates to destabilize kinetochore-microtubule interactions and eliminate incorrect attachments. These substrates must be dephosphorylated to stabilize correct attachments, but how opposing kinase and ph...
متن کاملEndogenous Protein Kinase Inhibitors
A thermostable inhibition of ATP:protein phosphotransferase (EC 2.7.1.37) (protein kinase) which is present in crude tissue extracts has been resolved by gel chromatography (Sephadex G-100) into two molecular forms. These two forms will be referred to as type I and type II inhibitor. The type I inhibitor (M, = 24,000) is specific for CAMP-dependent protein kinase and corresponds to the inhibito...
متن کاملControlling clots with Clk1
NF-κB, a central proinflammatory regulator, gets activated by TNF receptor–associated factors (TRAFs). But He et al. (page 2413) now report that one TRAF family member (TRAF3) instead negatively regulates an alternative NF-κB activation pathway. Classical activation of NF-κB occurs by TRAF-controlled degradation of cytoplasmic inhibitory binding proteins, which leads to nuclear accumulation of ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Nature Microbiology
سال: 2020
ISSN: 2058-5276
DOI: 10.1038/s41564-020-0745-6